Boston Scientific lifts annual profit forecast on strong demand for heart devices
Oct 23 (Reuters) -Boston Scientific BSX.N raised its annual profit forecast and exceeded Wall Street's estimates for third-quarter profit on Wednesday, driven by robust demand for its heart devices, sending its shares higher 1.1% to $88.94 in premarket trading.
Medical device makers have been benefiting from elevated demand for non-urgent surgeries in recent quarters, as Americans, especially the elderly, catch up on procedures deferred during the pandemic.
Larger rival Abbott Laboratories ABT.N raised its annual profit forecast slightly last week, on strong demand for its medical devices, including those used to manage diabetes.
Boston Scientific, which generates most of its revenue from sales of its heart devices such as pacemakers and stents, also makes equipment for diagnosing and treating a range of gastrointestinal and pulmonary conditions.
It now expects 2024 adjusted earnings per share of $2.45 to $2.47, compared with its previous per-share forecast range of $2.38 to $2.42. Analysts expect a profit of $2.41 per share for the year, according to estimates compiled by LSEG.
The Massachusetts-based company's revenue increased 19.4% to $4.21 billion for the quarter ended Sept. 30, compared with analysts' expectation of $4.04 billion.
Sales at its cardiovascular unit rose 25% to $2.73 billion, beating analysts' average estimate of $2.62 billion.
Boston Scientific struck a $1.6 billion deal in June to buy Silk Road Medical SILK.O, to gain access to its medical devices used for stroke prevention. It also markets its own stroke prevention product, branded Watchman.
The company's endoscopy unit, which includes devices used in surgical procedures that aid in weight loss, reported revenue of $678 million, up nearly 8% from a year earlier. Analysts had expected the unit to report sales of $676.6 million.
On an adjusted basis, Boston Scientific earned 63 cents per share in the reported quarter, compared with an estimate of 59 cents per share.
Reporting by Mariam Sunny in Bengaluru; Editing by Pooja Desai
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
